Biomarin Pharmaceutical (BMRN) Gains from Sales and Divestitures (2011 - 2018)
Biomarin Pharmaceutical (BMRN) recorded quarterly Gains from Sales and Divestitures of $963062.0 in Q4 2018, up 14.93% on a QoQ basis from $837926.0 in Q4 2017, and up 14.93% year-over-year from $837926.0 in Q4 2017.
Biomarin Pharmaceutical (BMRN) Gains from Sales and Divestitures (2011 - 2018) Analysis & Trends
Biomarin Pharmaceutical has disclosed Gains from Sales and Divestitures across 6 years of filings, most recently posting $963062.0 for Q4 2018.
- Quarterly Gains from Sales and Divestitures rose 14.93% year-over-year to $963062.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $963062.0 (up 14.93% YoY) and the FY2018 annual result came in at $963062.0, up 14.93% from the prior year.
- Gains from Sales and Divestitures grew to $963062.0 in Q4 2018, from $837926.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $963062.0 in Q4 2018 and troughed at $383332.0 in Q4 2014.
- A 5-year average of $684964.8 and a median of $751203.0 in 2016 frame the typical range for Gains from Sales and Divestitures.
- Annual changes were most pronounced in 2016 — Gains from Sales and Divestitures soared 53.53% — and 2017, when it climbed 11.54%.
- Tracing BMRN's Gains from Sales and Divestitures over 5 years: stood at $383332.0 in 2014, then advanced by 27.64% to $489301.0 in 2015, then surged by 53.53% to $751203.0 in 2016, then advanced by 11.54% to $837926.0 in 2017, then gained by 14.93% to $963062.0 in 2018.
- Business Quant data shows BMRN's Gains from Sales and Divestitures at $963062.0 in Q4 2018, $837926.0 in Q4 2017, and $751203.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 963,062.00 |
| Dec 31, 2018 | 963,062.00 |
| Dec 31, 2017 | 837,926.00 |
| Dec 31, 2017 | 837,926.00 |
| Dec 31, 2016 | 751,203.00 |
| Dec 31, 2016 | 751,203.00 |
| Dec 31, 2015 | 489,301.00 |
| Dec 31, 2015 | 489,301.00 |
| Dec 31, 2014 | 383,332.00 |
| Dec 31, 2014 | 383,332.00 |
| Dec 31, 2011 | 157,709.00 |
| Dec 31, 2011 | 157,709.00 |